Literature DB >> 33550542

Utility estimations of health states of older Australian women with atrial fibrillation using SF-6D.

Shazia S Abbas1, Tazeen Majeed2, Natasha Weaver2, Balakrishnan R Nair2, Peta M Forder2, Julie E Byles2.   

Abstract

PURPOSE: To estimate SF-6D utility scores for older women with atrial fibrillation (AF); calculate and compare mean utility scores for women with AF with various demographic, health behaviours, and clinical characteristics; and develop a multivariable regression model to determine factors associated with SF-6D utility scores.
METHODS: This study evaluated N = 1432 women diagnosed with AF from 2000 to 2015 of the old cohort (born 1921-26) of the Australian Longitudinal Study on Women's Health (ALSWH) who remained alive for at least 12 months post first recorded AF diagnosis. Self-reported data on demographics, health behaviours, health conditions, and SF-36 were obtained from the ALSWH surveys, corresponding to within three years of the date of the first record of AF diagnosis. Linked Pharmaceutical Benefits Scheme (PBS) data determined the use of oral anticoagulants and comorbid conditions, included in CHA2DS2-VA (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or TIA, Vascular disease and Age 65-74 years) score calculation, were assessed using state-based hospital admissions data. Utility scores were calculated for every woman from their SF-36 responses using the SF-6D algorithm with Australian population norms. Mean utility scores were then calculated for women with various demographic, health behaviours, and clinical characteristics. Ordinary Least Square (OLS) regression modelling was performed to determine factors associated with these utility scores. Two different scenarios were used for the analysis: (1) complete-case, for women with complete data on all the SF-36 items required to estimate SF-6D (N = 584 women), and (2) Multiple Imputation (MI) for missing data, applied to missing values on SF-36 items (N = 1432 women). MI scenario was included to gauge the potential bias when using complete data only.
RESULTS: The mean health utility was estimated to be 0.638 ± 0.119 for the complete dataset and 0.642 ± 0.120 for the dataset where missing values were handled using MI. Using the MI technique, living in regional and remote areas ([Formula: see text]) and the use of oral anticoagulants ([Formula: see text] were positively associated with health utility compared to living in major cities and no use of anticoagulants, respectively. Difficulty to manage on available income [Formula: see text], no/low physical activity [Formula: see text], disability [Formula: see text], history of stroke ([Formula: see text] and history of arthritis [Formula: see text] were negatively associated with health utility.
CONCLUSION: This study presents health utility estimates for older women with AF. These estimates can be used in future clinical and economic research. The study also highlights better health utilities for women living in regional and remote areas, which requires further exploration.

Entities:  

Keywords:  Atrial fibrillation; Health utilities; Linked data; Multiple imputations; Older women; Quality of life

Year:  2021        PMID: 33550542     DOI: 10.1007/s11136-020-02748-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  22 in total

1.  Health status: types of validity and the index of well-being.

Authors:  R M Kaplan; J W Bush; C C Berry
Journal:  Health Serv Res       Date:  1976       Impact factor: 3.402

2.  New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome.

Authors:  K H Humphries; C R Kerr; S J Connolly; G Klein; J A Boone; M Green; R Sheldon; M Talajic; P Dorian; D Newman
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

3.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

Authors:  Simon Stewart; Carole L Hart; David J Hole; John J V McMurray
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

4.  Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature.

Authors:  Gaurav Aggarwal; Giuseppe Lippi; Brandon Michael Henry
Journal:  Int J Stroke       Date:  2020-04-20       Impact factor: 5.266

5.  Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation.

Authors:  John Spertus; Paul Dorian; Rosemary Bubien; Steve Lewis; Donna Godejohn; Matthew R Reynolds; Dhanunjaya R Lakkireddy; Alan P Wimmer; Anil Bhandari; Caroline Burk
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-12-15

Review 6.  Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century.

Authors:  Jocasta Ball; Melinda J Carrington; John J V McMurray; Simon Stewart
Journal:  Int J Cardiol       Date:  2013-02-04       Impact factor: 4.164

7.  Burden of atrial fibrillation and stroke risk among octagenarian and nonagenarian women in Australia.

Authors:  Shazia Shehzad Abbas; Tazeen Majeed; Balakrishnan R Nair; Peta Forder; Natasha Weaver; Julie Byles
Journal:  Ann Epidemiol       Date:  2020-03-03       Impact factor: 3.797

8.  Patterns of Medications for Atrial Fibrillation Among Older Women: Results From the Australian Longitudinal Study on Women's Health.

Authors:  Shazia Shehzad Abbas; Tazeen Majeed; Balakrishnan R Nair; Peta M Forder; M Biostatistics; Natasha Weaver; Julie E Byles
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-08-06       Impact factor: 2.457

Review 9.  Women with atrial fibrillation: Greater risk, less attention.

Authors:  Annabelle S Volgman; Marian F Manankil; Disha Mookherjee; Richard G Trohman
Journal:  Gend Med       Date:  2009-09

10.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.